<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35239524</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Prognostic Factors of Bone Metastases From Colorectal Cancer in the Era of Targeted Therapy.</ArticleTitle><Pagination><StartPage>401</StartPage><EndPage>409</EndPage><MedlinePgn>401-409</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002270</ELocationID><Abstract><AbstractText Label="BACKGROUND">Various prognostic factors have been reported for bone metastases from different primary tumor sites. However, bone metastases from colorectal cancer are very rare, and the prognostic factors have not been investigated in detail.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to identify prognostic factors of bone metastases from colorectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective cohort study using data from a prospectively collected database.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at a single tertiary care cancer center in Japan.</AbstractText><AbstractText Label="PATIENTS">Patients who developed bone metastases from colorectal cancer during the study period among all patients who received initial treatment for colorectal cancer at our hospital between 2005 and 2016 (n = 4538) were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Overall survival after diagnosis of bone metastases from colorectal cancer was the main outcome measure.</AbstractText><AbstractText Label="RESULTS">Ninety-four patients developed bone metastases during the study period. The 5-year overall survival rate was 11.0%. Multivariable analysis identified the following independent risk factors associated with poor prognosis: &#x2265;70 years of age at diagnosis of bone metastases (HR, 2.48; 95% CI, 1.24-4.95; p &lt; 0.01), curative surgery not performed as initial treatment (HR, 2.54; 95% CI, 1.24-5.19; p = 0.01), multiple bone metastases (HR, 2.44; 95% CI, 1.30-4.57; p &lt; 0.01), albumin level &lt;3.7&#x2009;g/dL (HR, 3.80; 95% CI, 1.95-7.39; p &lt; 0.01), CEA &#x2265;30&#x2009;ng/mL (HR, 1.94; 95% CI, 1.09-3.46; p = 0.02), and less than 3 chemotherapy options remaining at diagnosis of bone metastases (HR, 2.83; 95% CI, 1.51-5.30; p &lt; 0.01). The median survival times for patients with 0-2, 3, and 4-6 risk factors were 25.0, 8.8, and 4.3 months, respectively.</AbstractText><AbstractText Label="LIMITATIONS">The main limitation is the single-center, retrospective design of this study.</AbstractText><AbstractText Label="CONCLUSIONS">Our results may facilitate multidisciplinary decision-making in patients with bone metastases from colorectal cancer. See Video Abstract at http://links.lww.com/DCR/B930 .</AbstractText><AbstractText Label="FACTORES PRONSTICOS DE LAS METSTASIS SEAS DEL CNCER COLORRECTAL EN LA ERA DE LA TERAPIA DIRIGIDA">ANTECEDENTES:Se han reportado varios factores pron&#xf3;sticos para las met&#xe1;stasis &#xf3;seas de diferentes sitios de tumores primarios. Sin embargo, las met&#xe1;stasis &#xf3;seas del c&#xe1;ncer colorrectal son muy raras y los factores pron&#xf3;sticos no se han investigado en detalle.OBJETIVO:Identificar los factores pron&#xf3;sticos de las met&#xe1;stasis &#xf3;seas del c&#xe1;ncer colorrectal.DISE&#xd1;O:Estudio de cohorte retrospectivo utilizando datos de una base de datos recolectada prospectivamente.ENTORNO CLINICO:Un solo centro oncol&#xf3;gico de atenci&#xf3;n terciaria en Jap&#xf3;n.PACIENTES:Se seleccionaron pacientes que desarrollaron met&#xe1;stasis &#xf3;seas de c&#xe1;ncer colorrectal durante el per&#xed;odo de estudio entre todos los pacientes que recibieron tratamiento inicial para el c&#xe1;ncer colorrectal en nuestro hospital entre 2005 y 2016 (n = 4538).MEDIDA DE RESULTADO PRINCIPAL:Supervivencia general despu&#xe9;s del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas por c&#xe1;ncer colorrectal.RESULTADOS:Noventa y cuatro pacientes desarrollaron met&#xe1;stasis &#xf3;seas, lo que representa el 2,0% de todos los pacientes con c&#xe1;ncer colorrectal que comenzaron el tratamiento durante el per&#xed;odo de estudio. La tasa de supervivencia global a 5 a&#xf1;os fue del 11,0 %. El an&#xe1;lisis multivariable identific&#xf3; los siguientes factores de riesgo independientes asociados con mal pron&#xf3;stico: edad &#x2265;70 a&#xf1;os al momento del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas (hazard ratio 2,48, CI del 95 % 1,24-4,95, p &lt; 0,01), cirug&#xed;a curativa no realizada como tratamiento inicial (hazard ratio 2,54, CI 95 % 1,24-5,19, p = 0,01), met&#xe1;stasis &#xf3;seas m&#xfa;ltiples (hazard ratio 2,44, CI del 95 % 1,30-4,57, p &lt; 0,01), nivel de alb&#xfa;mina &lt;3,7 g/dL (hazard ratio 3,80, CI del 95 % 1,95 -7,39, p &lt; 0,01), ant&#xed;geno carcinoembrionario &#x2265;30 ng/mL (hazard ratio 1,94, CI del 95 % 1,09-3,46, p = 0,02) y menos de 3 opciones de quimioterapia restantes al momento del diagn&#xf3;stico de met&#xe1;stasis &#xf3;seas (hazard ratio 2,83, 95 % CI 1,51-5,30, p &lt; 0,01). La mediana de los tiempos de supervivencia para los pacientes con 0-2, 3 y 4-6 factores de riesgo fue de 25,0, 8,8 y 4,3 meses, respectivamente.LIMITACIONES:Dise&#xf1;o retrospectivo de un solo centro.CONCLUSI&#xd3;N:Nuestros resultados pueden facilitar la toma de decisiones multidisciplinares en pacientes con met&#xe1;stasis &#xf3;seas de c&#xe1;ncer colorrectal. Consulte Video Resumen en http://links.lww.com/DCR/B930 . (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Yasunobu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shida</LastName><ForeName>Dai</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Frontier Surgery, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boku</LastName><ForeName>Narikazu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudose</LastName><ForeName>Yozo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imaizumi</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanemitsu</LastName><ForeName>Yukihide</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35239524</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002270</ArticleId><ArticleId IdType="pii">00003453-202303000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394&#x2013;424.</Citation></Reference><Reference><Citation>Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490&#x2013;1502.</Citation></Reference><Reference><Citation>Zhenghong, Zhu Z, Guoweijian, . Retrospective study of predictors of bone metastasis in colorectal cancer patients. J Bone Oncol. 2017;9:25&#x2013;28.</Citation></Reference><Reference><Citation>Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ. Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer. 2009;9:274.</Citation></Reference><Reference><Citation>Sun C, Deng Y, Zhou H, Hu ZQ. Risk factors for the development of metachronous bone metastasis in colorectal cancer patients after curative resection. Int J Surg. 2015;21:145&#x2013;149.</Citation></Reference><Reference><Citation>Kawamura H, Yamaguchi T, Yano Y, et al. Characteristics and prognostic factors of bone metastasis in patients with colorectal cancer. Dis Colon Rectum. 2018;61:673&#x2013;678.</Citation></Reference><Reference><Citation>Zhang L, Gong Z. Clinical characteristics and prognostic factors in bone metastases from lung cancer. Med Sci Monit. 2017;23:4087&#x2013;4094.</Citation></Reference><Reference><Citation>Chen S, Wang L, Qian K, et al. Establishing a prediction model for prostate cancer bone metastasis. Int J Biol Sci. 2019;15:208&#x2013;220.</Citation></Reference><Reference><Citation>Kanthan R, Loewy J, Kanthan SC. Skeletal metastases in colorectal carcinomas: a Saskatchewan profile. Dis Colon Rectum. 1999;42:1592&#x2013;1597.</Citation></Reference><Reference><Citation>Yazdani A, Dorri S, Atashi A, Shirafkan H, Zabolinezhad H. Bone metastasis prognostic factors in breast cancer. Breast Cancer (Auckl). 2019;13:1178223419830978.</Citation></Reference><Reference><Citation>Choi SJ, Kim JH, Lee MR, Lee CH, Kuh JH, Kim JR. Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. World J Clin Oncol. 2011;2:326&#x2013;328.</Citation></Reference><Reference><Citation>Santini D, Tampellini M, Vincenzi B, et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol. 2012;23:2072&#x2013;2077.</Citation></Reference><Reference><Citation>Li A, K&#xe4;smann L, Rades D, Fu C. A scoring system to predict the development of bone metastasis after radical resection of colorectal cancer. Anticancer Res. 2017;37:5169&#x2013;5172.</Citation></Reference><Reference><Citation>Tokuhashi Y, Uei H, Oshima M, Ajiro Y. Scoring system for prediction of metastatic spine tumor prognosis. World J Orthop. 2014;5:262&#x2013;271.</Citation></Reference><Reference><Citation>Katagiri H, Okada R, Takagi T, et al. New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med. 2014;3:1359&#x2013;1367.</Citation></Reference><Reference><Citation>Baek SJ, Hur H, Min BS, Baik SH, Lee KY, Kim NK. The characteristics of bone metastasis in patients with colorectal cancer: a long-term report from a single institution. World J Surg. 2016;40:982&#x2013;986.</Citation></Reference><Reference><Citation>Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26:1358&#x2013;1365.</Citation></Reference><Reference><Citation>Shida D, Boku N, Tanabe T, et al. Primary tumor resection for stage IV colorectal cancer in the era of targeted chemotherapy. J Gastrointest Surg. 2019;23:2144&#x2013;2150.</Citation></Reference><Reference><Citation>Paulino Pereira NR, Mclaughlin L, Janssen SJ, et al. The SORG nomogram accurately predicts 3- and 12-months survival for operable spine metastatic disease: external validation. J Surg Oncol. 2017;115:1019&#x2013;1027.</Citation></Reference><Reference><Citation>Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209&#x2013;1214.</Citation></Reference><Reference><Citation>Jung M, Ahn JB, Chang JH, et al. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2011;101:49&#x2013;55.</Citation></Reference><Reference><Citation>Imaizumi J, Shida D, Narita Y, et al. Prognostic factors of brain metastases from colorectal cancer. BMC Cancer. 2019;19:755.</Citation></Reference><Reference><Citation>Ghori AK, Leonard DA, Schoenfeld AJ, et al. Modeling 1-year survival after surgery on the metastatic spine. Spine J. 2015;15:2345&#x2013;2350.</Citation></Reference><Reference><Citation>Ghuman S, Van Hemelrijck M, Garmo H, et al. Serum inflammatory markers and colorectal cancer risk and survival. Br J Cancer. 2017;116:1358&#x2013;1365.</Citation></Reference><Reference><Citation>Wang F, Li P, Li FS. Prognostic role of C-reactive protein to albumin ratio in colorectal cancer: a meta analysis. Medicine (Baltimore). 2019;98:e16064.</Citation></Reference><Reference><Citation>Wei Y, Xu H, Dai J, et al. Prognostic significance of serum lactic acid, lactate dehydrogenase, and albumin levels in patients with metastatic colorectal cancer. Biomed Res Int. 2018;2018:1804086.</Citation></Reference><Reference><Citation>Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.</Citation></Reference><Reference><Citation>McMillan DC, Watson WS, O&#x2019;Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39:210&#x2013;213.</Citation></Reference><Reference><Citation>Dotan E, Tew WP, Mohile SG, et al. Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumors. Cancer. 2020;126:1708&#x2013;1716.</Citation></Reference><Reference><Citation>Song M, Chan AT. The potential role of exercise and nutrition in harnessing the immune system to improve colorectal cancer survival. Gastroenterology. 2018;155:596&#x2013;600.</Citation></Reference><Reference><Citation>Bates T. A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys. 1992;23:217&#x2013;221.</Citation></Reference><Reference><Citation>Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509&#x2013;524.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33216497</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Does IBD Portend Worse Outcomes in Patients with Rectal Cancer? A Case-Matched Analysis.</ArticleTitle><Pagination><StartPage>1265</StartPage><EndPage>1275</EndPage><MedlinePgn>1265-1275</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000001666</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with IBD are at increased risk for developing colorectal cancer. However, overall survival and disease-free survival for rectal cancer alone in patients with IBD has not been reported.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to determine overall survival and disease-free survival for patients with rectal cancer in IBD versus non-IBD cohorts.</AbstractText><AbstractText Label="DESIGN">This is a retrospective cohort study.</AbstractText><AbstractText Label="SETTING">This study was conducted at an IBD referral center.</AbstractText><AbstractText Label="PATIENTS">All consecutive adult patients with IBD diagnosed with rectal cancer and at least 1 year of postsurgery follow-up were included and matched in a 1:2 fashion (age, sex, preoperative stage) with patients with rectal cancer who did not have IBD.</AbstractText><AbstractText Label="MAIN OUTCOMES MEASURES">Five-year overall survival and disease-free survival, 30-day postoperative complication, readmission, reoperation, and mortality rates were measured.</AbstractText><AbstractText Label="METHODS">Survival rates were calculated using Kaplan-Meier estimates. The association of risk factors and long-term outcomes was assessed using Cox proportion hazard models.</AbstractText><AbstractText Label="RESULTS">A total of 107 study patients with IBD who had rectal cancer were matched to 215 control patients; preoperative stages were as follows: 31% with stage I, 19% with stage II, 40% with stage III, and 10% with stage IV. Differences were observed (IBD vs non-IBD) in neoadjuvant chemotherapy (33.6% vs 52.6%, p = 0.001) and preoperative radiotherapy (35.5% vs 53.5%, p = 0.003). Postoperative complication rates were similar. On surgical pathology, patients with IBD had more lymphovascular invasion (12.9% vs 5.6%, p = 0.04) and positive circumferential resection margins (5.4% vs 0.9%, p = 0.03). On multivariable analysis, the diagnosis of IBD did not significantly impact long-term mortality (HR, 0.91; 95% CI, 0.53-1.57; p = 0.73) or disease-free survival (HR, 1.36; 95% CI, 0.84-2.21; p = 0.22).</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by its retrospective design and the use of single-center data.</AbstractText><AbstractText Label="CONCLUSIONS">Patients have rectal cancer with IBD and without IBD have similar long-term and disease-free survival, despite lower rates of neoadjuvant treatment and higher margin positivity in patients with IBD. See Video Abstract at http://links.lww.com/DCR/B271. &#xbf;LA ENFERMEDAD INFLAMATORIA INTESTINAL ACARREA PEORES RESULTADOS EN PACIENTES CON C&#xc1;NCER RECTAL? UN AN&#xc1;LISIS DE CASOS-COINCIDENTES: Los pacientes con enfermedad inflamatoria intestinal (EII) tienen un mayor riesgo de desarrollar c&#xe1;ncer colorrectal. Sin embargo, no se ha informado la supervivencia general y la supervivencia libre de enfermedad para el c&#xe1;ncer rectal solo en pacientes con EII.Determinar la supervivencia general y la supervivencia libre de enfermedad para pacientes con c&#xe1;ncer rectal en cohortes con EII versus sin EII.Estudio de cohorte retrospectivo.Centro de referencia para enfermedad inflamatoria intestinal.todos los pacientes adultos con EII diagnosticados con c&#xe1;ncer rectal, consecutives, y al menos un a&#xf1;o de seguimiento postoperatorio se incluyeron y se emparejaron de manera 1: 2 (edad, sexo, etapa preoperatoria) con pacientes con c&#xe1;ncer rectal sin EII.Se midieron la supervivencia general a cinco a&#xf1;os y la supervivencia libre de enfermedad, complicaciones postoperatorias a los 30 d&#xed;as, reingreso, reoperaci&#xf3;n y tasas de mortalidad.Las tasas de supervivencia se calcularon utilizando estimaciones de Kaplan-Meier. La asociaci&#xf3;n de factores de riesgo y resultados a largo plazo se evalu&#xf3; mediante modelos de riesgo de proporci&#xf3;n de Cox.Un total de 107 pacientes con EII y c&#xe1;ncer rectal se compararon con 215 pacientes de control; las etapas preoperatorias fueron las siguientes: 31% de Etapa I, 19% de Etapa II, 40% de Etapa III y 10% de Etapa IV. Se observaron diferencias (EII versus no EII) en quimioterapia neoadyuvante (33.6% frente a 52.6%, p = 0.001) y radioterapia preoperatoria (35.5% frente a 53.5%, p = 0.003). Las tasas de complicaciones postoperatorias fueron similares. En la patolog&#xed;a quir&#xfa;rgica, los pacientes con EII tuvieron m&#xe1;s invasi&#xf3;n linfovascular (12.9% frente a 5.6%, p = 0.04) y m&#xe1;rgenes de resecci&#xf3;n circunferencial positivos (5.4% frente a 0.9%, p = 0.03). En el an&#xe1;lisis multivariable, el diagn&#xf3;stico de EII no tuvo un impacto significativo en la mortalidad a largo plazo (HR 0.91; IC del 95%: 0.53-1.57, p = 0.73) o la supervivencia libre de enfermedad (HR 1.36; IC del 95%: 0.84-2.21, p = 0.22)Dise&#xf1;o retrospectivo, centro &#xfa;nico de datos.Los pacientes con EII y sin EII con c&#xe1;ncer rectal tienen una supervivencia similar a largo plazo y libre de enfermedad, a pesar de las tasas m&#xe1;s bajas de tratamiento sneoadyuvante y un mayor margen positivo en pacientes con EII. Consulte Video Resumen en http://links.lww.com/DCR/B271.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alsughayer</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grass</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Molly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Kellie L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lightner</LastName><ForeName>Amy L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072662" MajorTopicYN="N">Margins of Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="Y">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>15</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33216497</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000001666</ArticleId><ArticleId IdType="pii">00003453-202009000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526&#x2013;535.</Citation></Reference><Reference><Citation>Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn&#x2019;s disease. Aliment Pharmacol Ther. 2006;23:1097&#x2013;1104.</Citation></Reference><Reference><Citation>Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228&#x2013;1233.</Citation></Reference><Reference><Citation>Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn&#x2019;s disease with colonic involvement. Lancet. 1990;336:357&#x2013;359.</Citation></Reference><Reference><Citation>Askling J, Dickman PW, Karl&#xe9;n P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356&#x2013;1362.</Citation></Reference><Reference><Citation>Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48&#x2013;54.</Citation></Reference><Reference><Citation>Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813&#x2013;1816.</Citation></Reference><Reference><Citation>Breynaert C, Vermeire S, Rutgeerts P, Van Assche G. Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk? Acta Gastroenterol Belg. 2008;71:367&#x2013;372.</Citation></Reference><Reference><Citation>Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099&#x2013;105.</Citation></Reference><Reference><Citation>Romano M, DE Francesco F, Zarantonello L, et al. From inflammation to cancer in inflammatory bowel disease: molecular perspectives. Anticancer Res. 2016;36:1447&#x2013;1460.</Citation></Reference><Reference><Citation>Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest Endosc. 2015;81:489&#x2013;501.e26.</Citation></Reference><Reference><Citation>Kim BJ, Yang SK, Kim JS, et al. Trends of ulcerative colitis-associated colorectal cancer in Korea: a KASID study. J Gastroenterol Hepatol. 2009;24:667&#x2013;671.</Citation></Reference><Reference><Citation>Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287:G7&#x2013;G17.</Citation></Reference><Reference><Citation>Hughes RG, Hall TJ, Block GE, Levin B, Moossa AR. The prognosis of carcinoma of the colon and rectum complicating ulcerative colitis. Surg Gynecol Obstet. 1978;146:46&#x2013;48.</Citation></Reference><Reference><Citation>Lavery IC, Chiulli RA, Jagelman DG, Fazio VW, Weakley FL. Survival with carcinoma arising in mucosal ulcerative colitis. Ann Surg. 1982;195:508&#x2013;512.</Citation></Reference><Reference><Citation>Ritchie JK, Hawley PR, Lennard-Jones JE. Prognosis of carcinoma in ulcerative colitis. Gut. 1981;22:752&#x2013;755.</Citation></Reference><Reference><Citation>Ribeiro MB, Greenstein AJ, Sachar DB, et al. Colorectal adenocarcinoma in Crohn&#x2019;s disease. Ann Surg. 1996;223:186&#x2013;193.</Citation></Reference><Reference><Citation>Jewel Samadder N, Valentine JF, Guthery S, et al. Colorectal cancer in inflammatory bowel diseases: a population-based study in Utah. Dig Dis Sci. 2017;62:2126&#x2013;2132.</Citation></Reference><Reference><Citation>Shu X, Ji J, Sundquist J, Sundquist K, Hemminki K. Survival in cancer patients hospitalized for inflammatory bowel disease in Sweden. Inflamm Bowel Dis. 2011;17:816&#x2013;822.</Citation></Reference><Reference><Citation>Ording AG, Horv&#xe1;th-Puh&#xf3; E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn&#x2019;s disease: a nationwide population-based cohort study. Inflamm Bowel Dis. 2013;19:800&#x2013;805.</Citation></Reference><Reference><Citation>Ou B, Zhao J, Guan S, Lu A. Survival of colorectal cancer in patients with or without inflammatory bowel disease: a meta-analysis. Dig Dis Sci. 2016;61:881&#x2013;889.</Citation></Reference><Reference><Citation>Peyrin-Biroulet L, Lepage C, Jooste V, Gu&#xe9;ant JL, Faivre J, Bouvier AM. Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008). Inflamm Bowel Dis. 2012;18:2247&#x2013;2251.</Citation></Reference><Reference><Citation>Sobin LH. TNM klasifikacia zhubn&#xfd;ch n&#xe1;dorov. 2002.Kosice: ETC Grafo</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:874&#x2013;901.</Citation></Reference><Reference><Citation>Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854&#x2013;862.</Citation></Reference><Reference><Citation>Jess T, Gamborg M, Matzen P, Munkholm P, S&#xf8;rensen TI. Increased risk of intestinal cancer in Crohn&#x2019;s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724&#x2013;2729.</Citation></Reference><Reference><Citation>Gollins S, Sebag-Montefiore D. Neoadjuvant treatment strategies for locally advanced rectal cancer. Clin Oncol (R Coll Radiol). 2016;28:146&#x2013;151.</Citation></Reference><Reference><Citation>Habr-Gama A, S&#xe3;o Juli&#xe3;o GP, Perez RO. Nonoperative management of rectal cancer: identifying the ideal patients. Hematol Oncol Clin North Am. 2015;29:135&#x2013;151.</Citation></Reference><Reference><Citation>Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV Jr. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:335&#x2013;342.</Citation></Reference><Reference><Citation>Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol. 1996;91:44&#x2013;48.</Citation></Reference><Reference><Citation>Larsen M, Mose H, Gislum M, et al. Survival after colorectal cancer in patients with Crohn&#x2019;s disease: a nationwide population-based Danish follow-up study. Am J Gastroenterol. 2007;102:163&#x2013;167.</Citation></Reference><Reference><Citation>Jensen AB, Larsen M, Gislum M, et al. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish study. Am J Gastroenterol. 2006;101:1283&#x2013;1287.</Citation></Reference><Reference><Citation>Oua&#xef;ssi M, Maggiori L, Alves A, et al. Colorectal cancer complicating inflammatory bowel disease: a comparative study of Crohn&#x2019;s disease vs ulcerative colitis in 34 patients. Colorectal Dis. 2011;13:684&#x2013;688.</Citation></Reference><Reference><Citation>Smith JJ, Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer. J Clin Oncol. 2015;33:1797&#x2013;1808.</Citation></Reference><Reference><Citation>Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215&#x2013;1223.</Citation></Reference><Reference><Citation>Quirke P, Steele R, Monson J, et al.; MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821&#x2013;828.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>